Following a cancer diagnosis, dietary supplements are reportedly used by 20%-80% of individuals. Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. Reasons cited for such use include improving quality of life, reducing symptoms related to treatment and/or the disease process, and recommendation from medical practitioners; family and friends may also be an influence. However, controversy surrounds the use of dietary supplements, particularly during treatment-specifically, whether supplements affect treatment efficacy is unknown. This article discusses the evidence related to common dietary supplements used to prevent cancer or a recurrence. (Nutr Clin Pract. 2017;32:607-627) 
Reportedly, 50% of adults residing in the United States use dietary supplements on a regular basis for a variety of health reasons. [1] [2] [3] In a recent review by Kantor et al, overall supplement use by noninstitutionalized and nonmilitary adults in the United States remained stable from 1999 to 2012, although some differences were noted with adults aged 20-39 years reportedly using fewer supplements of any kind while supplement use increased in those aged ≥65 years. 3 When evaluating use of specific supplements, Kantor and colleagues found increases in the use of vitamin D (from 5.1% in 1999-2000 to 19% in 2011-2012) and fish oil supplements (from 1.9% in 1999-2000 to 16% in 2011-2012). 3 Various differences were also observed, with women and non-Hispanic white adults using supplements the most. Additionally, use was the highest among highly educated individuals as compared with survey responders reporting less than a high school education (65% vs 37%, respectively). 3 Reportedly, dietary supplements are used by 20%-85% of individuals after being diagnosed with cancer. 4, 5 Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. 6 Improved quality of life, reduced symptoms related to treatment and/or the disease process, and recommendation by medical practitioners are commonly cited reasons; family and friends may also be an influence. 7 Controversy, however, surrounds the use of dietary supplements, particularly when patients are undergoing treatment because it is unknown whether supplements affect treatment efficacy.
The results of studies exploring the effect of dietary supplements on cancer outcomes are mixed, with some studies reporting benefits and others finding significant adverse outcomes. 2, 8 This article discusses the evidence available in the literature regarding selected dietary supplements commonly used by cancer survivors (see Table 1 ).
Multivitamin/Mineral Supplements
Reportedly, a little over one-third of adults in the United States take a daily multivitamin/mineral (MVM) supplement to prevent developing chronic diseases, including cancer, despite the lack of data supporting their efficacy for such purposes. 3, 5 A variety of MVM supplements are available in the marketplace, with varying levels of vitamins and minerals. While many contain 100% of the daily value for ≥1 vitamins and some for minerals, no supplement contains 100% of the daily value for calcium, magnesium, phosphorus, or potassium. MVM supplements are also produced specifically for individual segments of the population, as supplements directly formulated for children, women, men, and older adults are widely available. Often, these supplements have been designed to provide higher or lower amounts of a particular vitamin and/or mineral for that market segment. For example, some supplements manufactured for women typically contain more iron than that in supplements developed for men.
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Several investigators have examined the relationship between MVM supplements and cancer. [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] The Physician's Health Study II-a large prospective double-blind primary prevention trial-randomized middle-age male physicians (N = 14,641) from 1997 to 2011 to either a MVM supplement (Centrum Silver) or placebo. 10 The primary study end points evaluated the impact of a daily MVM supplement vs a placebo in regard to total cancer incidence and major cardiovascular events. Predetermined secondary outcomes included incidence of site-specific cancers. Study results revealed that men taking a multivitamin supplement experienced a modest decrease in total cancer incidence (hazard ratio [HR] , 0.92; 95% CI, 0.86-0.998; P = .04), although there was no reduced risk for prostate cancer (the most common type of cancer diagnosed in men) or overall cancer mortality noted. The Vitamins and Lifestyle study reported similar findings regarding lung and pancreatic cancers. 12, 13 Conversely, Dawsey and colleagues reported that use of multivitamins did not reduce the risk for either esophageal or gastric cancers.
14 Similarly, several large cohort studies, including the Women's Health Initiative and the Women's Healthy Eating and Living, have not found any benefits related to taking multivitamin supplements for reducing the risk for cancer, risk for recurrence, or risk for mortality. 15, 16 Alternatively, the Cancer Prevention II Cohort study noted a decrease in colorectal cancer risk with the use of multivitamin supplements but only after 10 years of use. 17 Likewise, the Nurses' Health Study observed a decrease in colon cancer risk when multivitamin supplements were used for at least 15 years or longer. 18 Additionally, a nonsignificant weak relationship was seen for breast cancer risk with long-term use (5-9 years) in this study, while an increased risk for fatal non-Hodgkin's lymphoma was found with multivitamin supplement use for >10 years.
Multiple studies have evaluated whether taking an MVM supplement may provide any advantages to cancer survivors. Jatoi et al found that survival was longer (4.3 years) for patients with non-small cell lung cancer who used MVM supplements daily vs those who were nonusers. 4 After adjusting for various factors, including tumor stage, treatment, and age, the authors found a relative risk (RR) of death of 0.74 (95% CI, 0.44-0.65; P < .01) in favor of vitamin/mineral use. In breast cancer survivors, multivitamin use prior to diagnosis and extending to postdiagnosis was associated with a nonsignificant decreased risk of recurrence (HR, 0.76; 95% CI, 0.54-1.06) and total mortality (HR, 0.79; 95% CI, 0.56-1.12). Conversely, the Shanghai breast cancer survivor study reported no positive relationship between multivitamin use and radiation treatment for breast cancer. 20 Study investigators, however, have hypothesized that perhaps the dosages may have been insufficient to see protective benefits.
Wassertheil-Smoller et al also reported a 30% reduction in breast cancer mortality in MVM users vs nonusers (HR, 0.70; 95% CI, 0.55-0.91) in postmenopausal women with invasive breast cancer. 21 Despite these positive findings, Ng et al found no significant relationship between multivitamin use for survivors with stage III colon cancers after completion of surgery and adjuvant chemotherapy after 6 months of follow-up, although a secondary analysis of the data reflected improved disease-free survival for study participants ≤60 years of age, with no benefits noted in those >60. 22 The Life After Cancer Epidemiology study also found that breast cancer survivors who were consuming 5.5 servings of vegetables and fruits daily and exercising for approximately 16 h/wk experienced a 60%-70% decrease in dying from any cause when using multivitamins on a regular basis. 19 Therefore, it is difficult to sort out whether the multivitamins and/or a healthy lifestyle promoted the beneficial findings, given that using multivitamins was not found to provide any protection to women with unhealthy lifestyle practices, although taking multivitamin supplements was not associated with any risks. Alternatively, in the Iowa Women's Health study, Inoue-Choi et al found that mortality risk was 2.3 times higher with the use of folic acid supplements and 28% greater among multivitamin users, with a trend toward a greater risk for dying when an increasing number of supplements were used by cancer survivors with poor dietquality scores. 23 A trend for lower mortality risk was observed with higher diet-quality scores and multivitamin use, as well as the use of a greater number of dietary supplements, highlighting perhaps the role of dietary quality in affecting outcomes.
Summary
Given the conflicting study results described here, consumers and cancer survivors should not rely on using MVM supplements to prevent cancer. This is supported by leading national cancer organizations, including the American Institute for Cancer Research and the American Cancer Society (see its guidelines for nutrition and cancer prevention), as both recommend against using MVM supplements to prevent cancer. 24, 25 Consuming a prudent healthy diet rich in colorful fruits, vegetables, nuts, seeds, and whole grains is more likely to provide a 26 A comprehensive nutrition assessment should be completed to determine if the patient is exhibiting any signs of micronutrient deficiencies or is at high risk for developing a deficiency before supplements are recommended. The American Cancer Society does recommend that when using a MVM supplement, consumers should not choose those that provide >100% of the daily value for any nutrient. 25 
Vitamin D
Vitamin D, a fat-soluble vitamin, is commonly referred to as the "sunshine" vitamin, although many nutrition experts think that vitamin D should be classified as a hormone due to its many physiologic functions. 27 In addition to sun exposure, vitamin D can be obtained from dietary supplements and foods such as fatty fish, beef, eggs, cheese, cod liver oil, mushrooms, as well as fortified foods such as milk, orange juice, and breakfast cereals; however, endogenous vitamin D production following ultraviolet B exposure is the primary contributor to circulating levels. 28 A potential role for vitamin D in cancer prevention and treatment has been reported, as preclinical research has revealed that vitamin D possesses antitumorigenic properties (eg, anti-inflammatory, antiproliferative, proapoptotic, and immunomodulatory). 27 Additionally, observational studies reflect an inverse association between sunlight exposure and the incidence of many types of cancer. 20, [27] [28] [29] However, the results of epidemiologic studies have been more mixed.
The vitamin D metabolite 25-hydroxycholecalciferol, 25(OH)D, is the biomarker primarily used to assess vitamin D status in studies, since it reflects both dietary and endogenous synthesis. With an estimated half-life of 3 weeks, 25(OH)D is considered a better indicator of status than the activated form of vitamin D, 1,25(OH)2D, which has a half-life of 15 hours. 27 Additionally, 1,25(OH)2D is tightly controlled by the parathyroid hormone, with levels generally not reflecting a decrease until vitamin D deficiency is severe. However, challenges also exist with using 25(OH)D to reflect status, as levels are influenced by inflammation, season of the year, body weight, age, sunscreen usage, medications, diet, skin pigmentation, physical activity, and genetic polymorphisms. 27, 29 A clear inverse association has been reported between circulating 25(OH)D levels and incidence of several cancers, including breast, pancreatic, kidney, ovarian, colorectal, lung, and upper gastrointestinal cancers, as well as total cancer incidence. [29] [30] [31] [32] [33] [34] [35] [36] The few prospective randomized trials that have been completed thus far have not consistently supported these findings, however.
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Lung Cancer
Studies reflect that lower serum vitamin D levels are prevalent in cancer survivors with lung cancers, which may be concerning given that higher circulating levels are associated improved survival. 40 , 41 Zhou et al found that patients having tumors resected in summer months did better in terms of recurrence-free survival than patients undergoing surgery in the winter months. 40 Collectively, the data from 2 meta-analysis and numerous prospective observational studies have reported a lower risk for lung cancer with increasing circulating 25(OH)D levels. [40] [41] [42] [43] Chen et al noted a statistically significant 5% decreased risk for lung cancer with each 10-nmol/L increase in 25(OH)D values (RR, 0.95; 95% CI, 0.91-0.99) in their meta-analysis evaluating circulating vitamin D levels and lung cancer risk. 42 In the second meta-analysis, Zhang et al observed an RR of 0.83 (95% CI, 0.77-0.90) comparing lowest to highest 25(OH)D levels. 43 Based on circulating 25(OH)D levels, poorer survival and an increased risk for cancer recurrence have been reported by some investigators, while other studies have found no association. [44] [45] [46] [47] [48] Supplementation. There have been no studies evaluating the role of vitamin D supplementation for risk reduction regarding lung cancer as the primary study outcome, with the only evidence coming from studies that examined overall intake, including supplements. In the Women's Health Initiative, which enrolled postmenopausal women aged 50-79 years, an inverse statistically significant association was found between vitamin D intake (from diet and supplements) and risk for lung cancer in never smokers. 48 A 63% reduction in risk was noted for intakes >800 IU/d (HR, 0.37) when compared with vitamin D intakes <100 IU/d. This suggests that vitamin D may provide additional risk reduction benefits in postmenopausal women in addition to not smoking. In a meta-analysis by Zhang et al, no statistical difference was found between vitamin D intake and lung cancer risk (RR, 0.89; 95% CI, 0.74-1.06; P = .184), although higher intakes (including supplements) were associated with a tendency for a lower risk for developing lung cancer. 43 No studies have been designed evaluating whether vitamin D supplementation can improve survival in this population.
Colorectal Cancer
Several meta-analyses have reported links between serum vitamin D levels and colorectal cancer, which suggests a consistent inverse relationship between serum levels and risk for colorectal cancer. 49, 50 Recently, a possible benefit between serum vitamin levels and survival in patients with metastatic colon cancer has been reported. 33, 51 In a phase III trial enrolling patients with metastatic colorectal cancers, Facciorusso et al found that study participants (n = 1043) with higher vitamin D levels at baseline experienced a significantly greater overall survival; increasing serum levels also resulted in better progression-free survival. 51 Patients in the upper quartile of vitamin D levels (median 25 
Breast Cancer
A number of studies have investigated the role of vitamin D and the risk of breast cancer, with inconsistent findings. Several meta-analyses have reported a statistically significant inverse relationship between serum 25(OH)D levels and risk for breast cancer. [54] [55] [56] However, in review of these studies, there is a clear and distinct difference in outcomes, with case-control studies reflecting a statistically significant decrease in breast cancer risk when circulating levels are higher and with prospective studies noting no significant association between breast cancer and circulating serum vitamin D levels.
In a recent study by Eliassen et al, no overall association was found between plasma 25(OH)D levels and risk for breast cancer, although a reduced risk was found for women having higher levels when compared with the those in the lowest quintile in the summer (RR, 0.66; 95% CI, 0.46-0.94; P trend = .01). 57 More recently, McDonnell et al reported that in women with 25(OH)D levels ≥40 ng/mL, a 67% lower risk of breast cancer was found vs women having serum levels <20 ng/mL (HR, 0.33; 95% CI, 0.12-0.90). 58 Whether vitamin D may play a role in the risk for breast cancer recurrence has also been examined. 59 Yao and colleagues found in the Pathways Study, a prospective cohort study of breast cancer survivors, that serum 25(OH)D levels were reduced in women with advanced-stage tumors; concentrations were also the lowest in premenopausal women with triple-negative cancer. 59 Study participants in the highest tertile of serum levels also had a greater overall survival, with the association remaining after controlling for confounding factors (HR 0.72; 95% CI, 0.54-0.98). Furthermore, a meta-analysis evaluated whether higher vitamin D levels at the time of diagnosis were associated with greater survival in women with breast cancer. Mohr and colleagues noted that higher serum levels were linked with a reduced mortality when compared with lower serum levels. 60 Meta-analyses by Kim and Je and Vrieling et al also reflect an improvement in survival, with higher 25(OH)D concentrations in breast cancer survivors. 61, 62 Supplementation. In a recent prospective randomized controlled trial (PRCT) of postmenopausal women, Lappe et al failed to find any benefits associated with daily vitamin D supplementation (2000 IU) when taken with calcium (1500 mg/d) vs placebo after 4 years. 38 Limitations to the study, however, were that women in the placebo group were allowed to take their own vitamin D supplements. Moreover, mean baseline vitamin D levels were found to be 32.8 ng/mL or within the normal range. These confounders may have possibly affected the lack of beneficial findings, but further research is needed to better determine whether vitamin D supplements are beneficial in primary prevention of breast cancer when serum levels are normal.
In the Women's Health Initiative trial, no benefit was found regarding a reduction in breast cancer among women taking vitamin D supplementation (400 IU/d), except for the women with very low vitamin D levels at baseline. 63 However, there was reportedly poor compliance with subjects consuming supplements, and many women were already taking supplements prior to study enrollment.
A retrospective study by Zeichner et al found that women receiving a little over 10,000 IU/week (≈1500 IU/d) of vitamin D while undergoing chemotherapy for breast cancer had a statistically significant improved disease-free survival in comparison with study participants undergoing the same treatment who were not taking vitamin D supplements. 64 Although investigators in these studies generally controlled for confounding variables-such as dietary vitamin D intake, body weight, physical activity levels, and stage of diseases-well-designed double-blind PRCTs are needed to better understand whether vitamin D supplementation can play a role in breast cancer.
Prostate Cancer
The results of studies completed to date with prostate cancer survivors and vitamin D levels are mixed, as some studies reflect no significant correlation, a decreased risk, or an increased in risk for prostate cancer. [65] [66] [67] [68] [69] [70] [71] A meta-analysis published in 2014, which included 21 studies, observed a statistically significant association (odds ratio, 1.17; 95% CI, 1.05-1.30) between higher circulating 25(OH)D levels and an increased risk for prostate cancer. 70 In the Selenium and Vitamin E Cancer Prevention Trial (SELECT), which included healthy men aged ≥50 years, levels ranging from 45 to 70 nmol/L were associated with a decreased risk when compared with levels that were low or high, although these findings were greater with Gleason scores of 7-10. 68 Findings also varied according to ethnicity, as no correlation was found with African American study participants and Gleason scores of 2-6, but a statistically significant decrease in prostate cancer risk was found with scores ranging from 7 to 10 in subjects with serum vitamin D levels >50 nmol/L. This evidence therefore appears to suggest that both very low and very high 25(OH)D levels are associated with an increased risk. These findings have been reported by others indicating that risk may be increased or decreased according to circulating values. 66, 69 Studies investigating vitamin D levels and morality are likewise equivocal. 67, 72, 73 Supplementation. Whether vitamin D supplementation may be beneficial for prevention of prostate cancer progression has been explored in only 1 clinical trial. Marshall et al investigated whether 4000 IU/d of vitamin D 3 for 1 year could prevent disease progression or affect prostate-specific antigen levels in men with low-risk prostate cancer when compared with historical controls. 71 While no differences in prostatespecific antigen levels were found between the groups, only 34% of the study participants in the intervention group experienced disease progression, as exhibited by increases in their Gleason scores or in the number of positive biopsy cores obtained, vs 63% in the historical control group. While these results suggest that some benefit may be derived from vitamin D supplementation, larger PRCTs are needed to confirm this finding. Additionally, trials should include a diverse population, as many of the studies completed thus far have primarily enrolled non-Hispanic white males. African American men have been found to consistently have lower circulating values of 25(OH)D, which is particularly important since African American men also have the highest incidence and rate of mortality related to prostate cancer. 74, 75 Kristal et al recommend that men >50 years old who use vitamin D supplements should have their levels monitored to avoid having levels exceeding 70 nmol/d. 68 
Pancreatic Cancer
Whether an association exists between circulating vitamin D concentrations and risk for pancreatic cancer has been explored. Pooled analysis of data from several large cohort studies noted a significant reduction in the risk for pancreatic cancer with higher concentrations of 25(OH)D. 76 An increased risk for pancreatic cancer with higher vitamin D levels has been found among heavy smokers. 77 Survivorship has been examined, as a retrospective study completed by McGovern and colleagues did not find any association between vitamin D concentrations and disease progression or survival in patients with pancreatic cancer between the highest and lowest quintiles (<20 and >60 ng/mL). 78 No studies have been completed examining the role of supplementation and pancreatic cancer risk or outcomes once diagnosed.
Other Cancers
Circulating vitamin D levels and clinical outcomes have been evaluated in other cancers. Hypovitaminosis D has been linked to poorer survival for cancer survivors with lymphoid cancers. 56, 79 Although no clinical studies have been completed regarding the role for vitamin D supplementation and outcomes in this patient population, the University of Iowa/ Mayo Clinic SPORE trial is currently underway exploring whether maintaining serum vitamin D levels >30 ng/dL can positively affect outcomes. 80 In patients with Barrett's esophagus, no association was found between circulating 25(OH)D levels and incidence of esophageal adenocarcinoma despite a high prevalence of vitamin D deficiency (23.6%) or insufficiency (34.7%). 81 However, in another study, patients receiving vitamin D supplements postoperatively for esophageal cancer had a longer diseasefree period, although there was no difference in overall survival. 82 The evidence regarding the risk for developing other types cancers and vitamin D values is limited, but some data appear to suggest that higher vitamin D levels are associated with a lower risk for developing kidney and bladder cancers. 83, 84 In contrast, a 2015 meta-analysis found no association between vitamin D values and risk for gastric cancer. 85 Additionally, 2 meta-analyses did not find any association between 25(OH)D levels and ovarian cancers.
86,87
Summary
In conclusion, although numerous studies have been conducted regarding vitamin D and risk for cancer, the lack of data from PRCT trials investigating whether benefits can be derived from vitamin D supplementation limit our ability to know whether vitamin D 3 supplementation alone or in combination with other nutrients can prevent cancer, recurrence, and cancer-specific mortality. The only completed PRCT completed thus far with the primary study outcome of all-type cancer incidence (excluding nonmelanoma skin cancers) found no benefit for vitamin D 3 (2000 IU/d) and calcium supplementation (1500 mg/d) vs placebo in healthy postmenopausal women after 4 years of supplementation. 38 Unfortunately, this study did not examine whether vitamin D supplementation alone might be beneficial. Moreover, study participants had a mean baseline serum 25(OH)D of 32.8 ng/mL, within the reference range, although post hoc analysis did reveal that with 25(OH)D levels of 30 ng/mL at baseline, the estimated HR for cancer incident with values between 30 and 55 ng/mL was 0.65 (95% CI, 0.44-0.97).
While serum levels >20 ng/mL are recommended for bone health, clarity is needed regarding whether an optimal level exists for the primary prevention of cancer or for reduction in risk of recurrence and morality. Whether lower levels of 25(OH)D are associated with cancer risk or recurrence or are a consequence of the disease is also unknown. Vitamin D is considered an acute-phase reactant and thus affected by inflammatory status. Hence, it is difficult to know whether increasing serum concentrations in the face of inflammation, which is commonly associated with cancer, can positively affect outcomes, requires further research. However, bone density can be adversely affected by cancer and many oncologic therapies. Vitamin D supplementation is considered safe and affordable and thus should be recommended to avoid hypovitaminosis D to maintain or promote skeletal health. 88 To address the current gaps in research, future studies exploring the impact of vitamin D supplementation on circulating levels and the risk for cancer and cancer recurrence should measure (1) circulating levels in individuals at high risk for developing cancer and (2) levels at various time points, starting with before diagnosis, at the time of diagnosis, and throughout the continuum of survival until death, to better understand if circulating vitamin D levels play any role in promoting survival in the cancer survivor population. Supplementation should be in doses sufficient to achieve levels associated with beneficial effects. Confounding factors-such as dietary and supplement intake, body weight, physical activity patterns, season, skin pigmentation, sunscreen use, and sun exposureshould be taken into consideration, since many of these factors can adversely affect levels. The presence and impact of genetic polymorphisms should be evaluated, given an observed link with outcomes. Studies need to ascertain at which level is circulating 25(OH)D ideal for reducing the risk for cancer and recurrence, as well as what doses of supplementation should be prescribed to achieve optimal levels, since no guidelines for vitamin D supplementations for cancer survivors exist. Finally, studies should be designed where cancer prevention or cancer outcomes, such as recurrence and mortality, are the primary outcomes.
Last, reportedly 80% of the U.S. adult population has serum 25(OH)D levels <30 ng/mL, with another 30% having circulating levels <20 ng/mL. 38 Since vitamin D is naturally found in few food sources, ultraviolet B exposure is the largest contributor to circulating levels. Ultraviolet B radiation is insufficient for vitamin D synthesis from November to early May in latitudes at approximately 40 degrees north and 40 degrees south. 89 Given that vitamin D supplementation is generally regarded as safe and affordable, supplementation should be recommended to achieve adequate levels, as established by clinical practice guidelines, to derive possible benefits for risk reduction of cancer as well as for many other chronic diseases. 88 To better answer the question regarding if vitamin D supplementation can play a role in the primary prevention of cancer, the Vitamin D and Omega-3 Trial is currently underway. This trial is exploring whether any benefits may be derived from 2000 IU/d of vitamin D β-Carotene β-carotene, a precursor to vitamin A, is a plant phytonutrient found in many red and orange fruits and vegetables. The purported benefits of β-carotene ingestion for chemoprevention are associated with its antioxidant and immunostimulant properties. A number of studies have explored whether a higher dietary intake of the carotenoids, particularly β-carotene, from supplements provides health benefits similar to findings of epidemiologic studies suggesting that lower serum levels of antioxidants may be associated with an increased cancer risk. 8, [90] [91] [92] [93] [94] Thus far, the data are inconsistent. In the landmark AlphaTocopherol and Beta-Carotene Cancer Prevention Trial, highdose supplementation with β-carotene significantly increased the incident of lung cancer. 8 The key aim of this double-blinded primary prevention PRCT was to investigate whether supplementation with β-carotene, alone or with α-tocopherol, would prevent lung cancer in a high-risk population-male smokers. In this trial, 29,133 male Finnish smokers were randomized to 1 of 4 groups: 20 mg/d of β-carotene, 50 mg/d of dl-α-tocopherol, both, or placebo. Supplements were consumed for a range of 5-8 years, with a mean follow-up of 6.1 years. Study results reflected a 16% increase in the incidence of lung cancer (RR, 1.16; 95% CI, 1.02-1.33; P = .02) in study participants and an 8% increase in overall mortality (RR, 1.08; 95% CI, 1.01-1.16; P = .02) in the groups supplemented with β-carotene. These results were a surprise given that ecologic studies had previously indicated a reduced risk for lung cancer with high fruit and vegetable intakes, thereby reflecting a significant difference related to obtaining a nutrient from supplementation vs dietary sources. 90, 91 These findings were further supported by the U.S. CARET (Beta-Carotene and Retinol Efficacy Trial), which found that supplementation with 30 mg/d of β-carotene plus 25,000 IU/d of retinyl palmitate, in a high-risk population (current smokers, recent smokers, and exposed to asbestos) that included participants of both sex, was associated with a 28% increase in the incidence of lung cancer (RR, 1.28; 95% CI, 1.04-1.57; P = .02) and a 17% increase in all-cause mortality (RR, 1.17; 95% CI, 1.03-1.33; P = .02) after 4 years of follow-up. 9 This trial was stopped early due to the increased incidence of lung cancer and mortality demonstrated in the study subjects consuming the β-carotene and retinol supplements. Importantly, in their posttrial follow-up of the initial Alpha-Tocopherol, BetaCarotene Cancer Prevention (ATBC) study of participants taking β-carotene supplements, Virtamo et al found that the impact of β-carotene lingered and was associated with greater risk for lung cancer throughout the first 4 years posttrial, particularly in heavy smokers (>20 cigarettes per day). 92 In both the ATBC and CARET studies, lung cancer incidence was increased in men consuming >11 g/d of alcohol, although the association was null after discontinuation of supplements. 8, 9 The Vitamins and Lifestyle trial is the most recent published study to investigated the long-term use of β-carotene supplementation and incidence of lung cancer. 12 An 18% nonsignificant increase in the incidence of lung cancer was found with the use of β-carotene supplements for ≥4 years. An increased risk for non-small cell lung cancer was noted for those consuming individual lutein supplements as well as for total lung cancers. Interestingly, no increased risk was found when multivitamin supplements were taken in conjunction with β-carotene supplements.
Other studies have not reported an increased risk for lung cancers with use of β-carotene supplements. Neither the Physicians' Health Study-where supplementation with 50 mg of β-carotene every other day plus aspirin (325 mg every other day) or β-carotene plus aspirin placebo-nor the Women's Health Study, where β-carotene supplements (50 mg) were consumed every other day, found any increased risk for lung cancer related to β-carotene supplementations. 93, 94 However, both studies included low-risk populations.
While the exact mechanisms of how β-carotene promotes lung carcinogenesis are unknown, the prevailing hypothesis is that components in cigarette smoke may induce oxidation of the β-carotene resulting in a pro-oxidant effect. 95 In animal studies, the combination of cigarette smoke with β-carotene resulted in a potent proliferative effect on lung tissues. 96 In summary, high-dose β-carotene supplementation is associated with adverse effects by increasing the risk for lung cancer in tobacco users; long-term supplementation should especially be avoided by heavy smokers. There is no evidence that β-carotene supplements are harmful for low-risk individuals. 94, 95 More important, ingestion of high doses of β-carotene from foods has not been associated with any risks.
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Antioxidants
The production of reactive oxygen species (ROS) has been proposed to play a dual role in health, as ROS facilitate cell signaling and communication but can also adversely cause cell damage and alterations in gene expression promoting an oxidative environment. 97 In normal physiologic homeostasis, balance is achieved by countering ROS production with a variety of endogenous antioxidant defenses. However, excessive ROS synthesis can lead to alterations in redox balance, which in turn may stimulate tumorigenesis through cell signaling pathways that increase cellular proliferation, inhibit apoptosis, and facilitate cancer cell metabolic adaptation. 97 In an effort to decrease the risk for developing a number of chronic diseases, consumers, including cancer patients, are drawn to using antioxidant dietary supplements to combat the oxidative stress associated with developing such diseases.
Many chemotherapeutic agents-including commonly used drugs such as anthracyclines, bortezomib, capecitabine, cisplatin, and cyclophosphamide-act by inducing oxidative stress that leads to cancer cell death. Additionally, radiotherapy produces ROS, which causes cellular damage to healthy cells while destroying cancer cells. 96, 98 Therefore, controversy exists whether augmentation of endogenous antioxidant defenses (which are often depleted in cancer patients) with antioxidant supplementation can provide benefits (eg, alleviating ROS damage) and reduce common side effects associated with chemotherapy and radiation therapies. 97 Theoretically, it is thought that antioxidants may be advantageous by preventing DNA damage and oxidation while increasing cellular repair, blocking cell proliferation as well as cell transduction and signaling with increased apoptosis. 99 In practice, the fear has been that antioxidant supplementation may reduce the cytotoxic effects of antineoplastic therapies, thereby reducing treatment efficacy. 98, 100, 101 The results of studies, however, show that the impact of antioxidant supplementation on cancer cells is dose dependent, with greater doses inhibiting the type of antioxidant and type of cancer, with some being inhibitory and with others possibly promoting cancer growth.
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Use for Cancer Prevention
When referring to antioxidants commonly used, most studies have examined if benefits could be derived from supplementation with β-carotene, vitamins C and E, and/or selenium. In 1 of the largest PRCTs, healthy Chinese men and women residing in Linxian, China, who were at risk for developing gastric and esophageal cancers were randomized to receive either a combination of antioxidants, including β-carotene (15 mg/d), α-tocopherol (30 mg/d), and selenium (50 mcg/d), or placebo consumed daily for 5 years. 102 Initial study results reflected a reduction in mortality for gastric cancers but not esophageal cancers in study participants receiving supplementation; no reduction in risk for either cancer was found between the groups. Ten years after the trial was stopped, no reduction for risk of death related to either gastric or esophageal cancer was found between supplement users and nonusers. 103 The Women's Health Study, a double-blinded PRCT, found no benefits in incidence of cancer for women taking either 50 mg of β-carotene every other day or placebo. 104 No reduction in cancer risks were seen for the women receiving vitamin E supplements (600 IU every other day) on follow-up after an average of 10.1 years. 104, 105 Additionally, the Women's Antioxidant Cardiovascular Study, which enrolled approximately 8171 women at high risk for cardiovascular disease, observed no statistically significant benefit for cancer risk reduction with use of vitamin C supplements (500 mg/d), vitamin E supplements (600 IU every other day), or β-carotene (50 mg every other day) after a mean follow-up of 9.4 years when compared with the placebo group. 106 The Supplémentation en Vitamines et Minéraux Antioxydants Study results noted no decreased risk on the incidence for cancer or all-cause mortality in healthy French study participants taking a combination of antioxidant supplements daily, including vitamin C (120 mg), vitamin E (30 mg), β-carotene (6 mg), selenium (100 mcg), and zinc (20 mg), when compared with the placebo group after an average follow-up of 9.4 years of treatment. 107 Of note, when the data were analyzed separately, a lower total cancer incidence and a lower all-cause mortality rate were found for men taking the supplements vs women, although this benefit disappeared 5 years after supplementation was stopped. Thus, in totality, there appears to be no benefits associated with taking a variety of antioxidant supplements for the primary prevention of cancer.
Use During Treatment
Studies using β-carotene and vitamin E in patients undergoing radiotherapy for head/neck cancers have yielded mixed results (see Table 2 ). [108] [109] [110] While supplementation reduced the severity of side effects (eg, mucositis), the study participants receiving supplementation experienced a reduction in survival, although this was later seen in subgroup analysis among only those who smoked. In breast cancer survivors, supplementation with β-carotene, niacin, vitamin C, coenzyme Q10, selenium, and possibly zinc in varying doses resulted in a decrease in breast cancer-specific survival and disease-free survival in the supplement group. 111 In contrast, a randomized controlled trial completed by Pathak and colleagues found a nonsignificant trend for a slightly greater response rate to chemotherapy and survival in study participants with stage IIIb-IV non-small cell lung cancer receiving a combination supplement (vitamin C, α-tocopherol, and β-carotene) in comparison with the nonsupplemented group. 112 Additionally, an 18% decrease in mortality risk (HR, 0.82; 95% CI, 0.65-1.02) and a 22% reduced recurrence risk (HR, 0.78; 95% CI, 0.63-0.95) were observed in women residing in Shanghai, China, who used vitamin E, vitamin C, or multivitamins within the first 6 months after being diagnosed with breast cancer, independent of disease stage, lifestyle factors, sociodemographic status, or whether participants were receiving chemotherapy or not. 20 However, a nonsignificant increased risk for mortality or recurrence was found for study participants who either took or did not take antioxidant supplements while receiving radiation treatment. Last, a systematic review by Block et al in 2007 concluded that there is no interaction between cancer treatment and antioxidants and that antioxidant supplementation can enhance cytotoxic effects and improve patient survival. 98 In a more recent systematic review by Yasenda et al, the authors concluded that they could not determine if the use of antioxidant supplements during chemotherapy and/ or radiation affected treatment outcomes or improved the side effects related to treatment. 99 In summary, it is unknown whether antioxidant supplements may provide any benefits or harm to cancer patients undergoing treatment. Most studies have used a various types and doses of antioxidants and have included patients undergoing a variety of treatment regimens with numerous types of cancer, thus making it difficult to determine the true impact of using antioxidant supplements during treatment. Future studies need to investigate the single use of agents, as well as mixtures and standardized dosages, and enroll study participants with the same type of cancer who are undergoing the same treatment regimens to better understand the impact of supplementation in this patient population.
It has been suggested that antioxidant supplement use while receiving chemotherapy regimens associated with low oxidative stress production (purine/pyrimidine analogues, antimetabolites, monoclonal antibodies, vinca alkaloids, and corticosteroids) is less likely to be associated with any possible adverse interactions between supplements and treatments. 98 Caution should be taken, though, when using therapeutic levels of antioxidants during treatment with other cytotoxic agents, including alkylating, anthracyclines, platinum-based, antiangiogenic, or tyrosine kinase inhibitors.
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Vitamin E
Vitamin E, a fat-soluble vitamin, is another nutrient that has generated a lot of interest over the years, as α tocopheryl 113 Several investigators have examined the impact of vitamin E supplementation in regard to cancer. The Vitamins and Lifestyle study found a small but significant increase in risk for lung cancer among smokers secondary to, on average, a 10-year consumption of vitamin E supplementation for each 100-mg increase in dose (HR, 1.05; 95% CI, 1.00-1.09, P = .033) and every 100-mg/d increase in dose (HR, 1.07; 95% CI, 1.02-1.12; P = .004). 12 Similarly, the ATBC study noted a RR of 1.03 (95% CI, 0.91-1.16) between use of vitamin E supplements and risk of lung cancer in heavy smokers. 8 Conversely, Roswall et al found no association between vitamin E supplement intake and risk of lung cancer at a median follow-up of 10.6 years, although a protective effect was related to a high dietary vitamin E intake; smoking status did not have any effect on outcomes. 114 In an observational trial, Antwi et al investigated whether the use of vitamin E supplements was associated with prostate cancer risk in the North Carolina-Louisiana Prostate Cancer Project. 115 Study results showed no association with reported use of vitamin E supplements in the 12 months prior to study enrollment, with varying doses consumed. However, findings were very different with vitamin E supplementation in a PRCT. The SELECT was a PRCT that explored the effect of vitamin E and selenium supplementation on the incidence of prostate cancer in healthy men >50 years old, when taken either alone or together vs placebo. Initially, it was reported that neither vitamin E (400 IU/d) nor selenium (200 mcg/d) supplementation reduced the risk for prostate cancer, although a statistically nonsignificant increase in risk was found with vitamin E supplementation. 11 However, Klein et al noted an increased incidence of prostate cancer after 7 years of median follow-up in all supplemented groups (selenium alone, vitamin E alone or vitamin E plus selenium) when compared with the placebo group, although the increase was statistically significant only in the group receiving vitamin E alone (HR, 1.17; 99% CI, 1.004-1.36; P = .008). 116 The increase in risk became apparent with supplement use after 3 years and continued through follow-up. When adjusted for covariates, no significant association with risk was observed with vitamin E and selenium supplements when taken together. In contrast, the Physicians' Health Study II (PHS II) found no association between vitamin E supplement use and incidence of prostate cancer after approximately 12 years of follow-up. 117 The PHS II investigators note that differences in the 2 studies-namely, that vitamin E supplements (400 IU) were taken every other day during the intervention period in the PHS II study-may have made a difference. Risk may have also been increased in the SELECT, as many men were taking vitamin E supplements prior to study enrollment. Additionally, the SELECT included men from the general population, while the PHS II study enrolled physicians, who have a higher socioeconomic status and may practice healthier lifestyles. The PHS II trial did not find any benefit or adverse effect of vitamin E and other site-specific cancers or total cancer. Interesting, the SELECT group reported that study participants with higher α-tocopherol values prerandomization had a statistically significant increased risk for prostate cancer if they received the selenomethionine supplement either alone or in combination with vitamin E supplementation. 118 Further studies are warranted to evaluate this finding.
In a double-blind placebo-controlled trial of study participants with head/neck cancers undergoing radiotherapy, vitamin E supplementation as swish-and-swallow mouth rinses did not affect survival. 119 Furthermore, vitamin E supplementation reduced the severity of radiation-induced mucositis.
Vitamin E supplementation has been prescribed for reducing chemotherapy-induced neuropathy. Mixed results have been reported regarding supplement use and neurotoxicity in patients receiving vitamin E supplementation while undergoing chemotherapy with taxane-or platinum-based agents, with 2 studies reporting no benefits and 2 studies noting significant benefits.
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Summary
As described here, trials exploring vitamin E supplementation present conflicting findings in terms of whether it provides any benefits to survivors or for the prevention of cancer. Differences in study outcomes may be related to the dose (typically higher than dietary intake), the type of vitamin E used (eg, α-tocopherol vs mixed tocopherols), baseline status, and adherence. Vitamin E is not a single nutrient but is actually a family of phenolic compounds composed of 8 types of vitamin E isomers: 4 tocopherols (α, β, δ, and γ) and 4 tocotrienols (α, β, δ, and γ). α-tocopherol is the active form throughout the body in the blood and tissues, while γ-tocopherol is the most common form in the diet. 65 For example, γ-tocopherol is now thought to possess greater anti-inflammatory properties over α-tocopherol. 65 Given the potential adverse effects associated with high vitamin E doses (400 IU/d), particularly for men, vitamin E supplementation for cancer prevention or management is not recommended.
Vitamin C
Vitamin C is among the vitamins most often used or considered by oncology patients to gain the benefits associated with antioxidants. Unfortunately, the evidence is contradictory, making the decision about use difficult. In vitro studies have shown that high-dose vitamin C reduces cell proliferation of various cancers, including prostate, pancreatic, hepatocellular, and colon cancer, as well as mesothelioma and neuroblastoma. 124 Animal studies have produced similar positive results against pancreatic cancer, liver cancer, prostate cancer, sarcoma, mesothelioma, and ovarian cancer. 125 Early human trials in the 1970s, however, yielded conflicting results. [126] [127] [128] In an early study of terminal cancer patients, those treated with intravenous (IV) ascorbic acid had a longer mean survival time (300 days) than matched controls. 126, 127 Attempts to replicate these results using high doses of oral vitamin C have failed to find any differences in symptoms, survival, or performance status. [128] [129] [130] More recent publications are largely case reports or those that focus on the possibility of vitamin C ameliorating cancer treatment-related side effects and improving quality of life. [131] [132] [133] [134] [135] Perhaps the issue that has generated the most interest about vitamin C is whether or not it interferes with conventional cancer therapies. An often-cited study found that vitamin C given before several antineoplastic agents attenuated their efficacy against leukemia and lymphoma cell lines. 124 The same trial also demonstrated an antagonistic effect of vitamin C in mice treated with doxorubicin. Another animal study suggests that combining vitamin C with bortezomib interferes with the drug's ability. 135 However, a systematic review of 19 randomized controlled trials did not report any decrease in chemotherapy efficacy from antioxidant supplementation, of which vitamin C was 1 example. 131 Evidence is extremely limited regarding the efficacy of using vitamin C supplements, although 2 small trials in patients with pancreatic cancer have found high-dose vitamin C infusion in combination with gemcitabine to be well tolerated and to have a favorable effect on disease progression. 132, 133 Trials of high-dose IV vitamin C have produced varied results thus far and are ongoing. 125 A large (n = 4877) prospective cohort of Chinese women with breast cancer were asked about their use of vitamins and followed for 4 years on average. 20 Mortality was reduced by 44% and the risk of recurrence, by 38%, in women who took vitamin C for >3 months. This positive benefit was seen whether the women took the supplement during chemotherapy or not, suggesting that vitamin C did not have an antagonistic effect.
It is evident that there is little consensus of the role and safety of vitamin C during cancer therapy, and subsequently there are no definitive guidelines to direct patient use. Clinicians should consider cancer type and treatment plan in helping patients make informed decisions about the use of vitamin C.
ω-3 Fatty Acids
ω-3 fatty acid supplementation, particularly with eicosapentaenoic acid (EPA) and docosahexaenoic acid, has been actively explored, as preclinical and intervention trials have demonstrated antitumor and anticachectic benefits. Upregulation in nuclear factor κB activity is associated with promoting cancer cachexia in animal models, resulting in enhanced proteolysis and apoptosis in the myotubes and leading to protein degradation via activation of the ubiquitin proteasome pathway. 136 Laboratory studies reveal that EPA may prevent protein breakdown by inhibiting nuclear factor κB buildup in the cell nucleus. 136 The results of trials investigating the use of ω-3 fatty acid supplements for these reasons in cancer populations are mixed. [137] [138] [139] [140] [141] [142] [143] Recently, several investigators have examined whether such supplements may be beneficial for patients diagnosed with non-small cell lung cancer; improvements in body weight, lean tissue mass, functional status, and survival were demonstrated with supplementation of ≈2 g/d of EPA. 140, 142 A lean body is important for maintaining functional status and quality of life, but sarcopenia has been identified as a predictor of chemotherapy toxicity. 144, 145 While the results are promising, further validation of the findings is needed from the completion of large randomized controlled trials, as these studies are small. Compliance with supplementation has been reported as a key aspect that should be addressed in future studies.
Glutamine
Glutamine is an amino acid that is thought to become a "conditionally essential" amino acid during increased times of stress, due to its importance in maintaining redox balance and its role in stimulating immune function as well as serving as a fuel for the enterocytes. Glutamine supplementation has been explored in various studies to investigate whether supplementation may provide benefits for treatment-related side effects.
Mucositis, a common nutrition-impact symptom associated with chemotherapy and radiation, reportedly is experienced by >90% of head/neck cancer patients. 146 Symptoms including severe oropharyngeal pain and mucosal ulceration profoundly limit the ability to consume food and liquids. Quality of life is also adversely affected and may result in dose reduction and delays in treatment. 145 Good oral hygiene, opiate analgesics, nutrition support therapy providing adequate protein intake, and other strategies are employed to help limit the extent and severity. [146] [147] [148] Complementary strategies, such as the use of oral glutamine supplements (30 g/d divided in 3 doses), can reportedly reduce the severity, time to onset, and duration of mucositis in head/neck cancer patients and lessen weight loss. 147, 148 Wang et al investigated whether oral glutamine supplementation could reduce peripheral neuropathy induced by chemotherapy in patients being treated for colon or rectal cancer. 149 The glutamine group consumed 15 g twice per day for 7 consecutive days, every 2 weeks, beginning on the day of oxaliplatin infusion. There were no differences between the glutamine group and the placebo group in terms of response to chemotherapy or survival, but ability to complete activities of daily living was greater in the glutamine group, which also experienced less of a need to decrease its oxaliplatin doses (7.1% vs 27.3%). Additionally, among patients undergoing chemotherapy for colorectal cancers, when compared with nonusers, patients using glutamine supplements (18 g/d starting 5 days before chemotherapy and continuing for 15 days) reported less diarrhea and gut mucositis. 150 Conversely, no benefits were reported with use of glutamine supplements to reduce radiation enteritis in patients undergoing pelvic radiation for cancer.
In summary, oral glutamine supplementation appears beneficial for reducing mucositis related to radiotherapy for head/ neck cancers and may be beneficial for reducing gut mucositis and diarrhea, although further studies are needed given the conflicting results reported thus far.
Botanical and Other Supplements
Worldwide, plants have been used for healing since ancient times. 57 Only recently has the interest in using botanicals for medicine risen in the United States, while in Asia, South America, and Africa, the use of local plants is a primary component of medical treatment. In fact, the alkaloid-based chemotherapeutic agents used to treat certain cancers are derived from plants. 152 Consumers, including cancer patients, are drawn to botanical supplements, also known as herbal remedies, because they are natural and thus considered safe. Botanical supplements are often used to improve health, stimulate immune function, relieve treatment-related side effects, and improve quality of life. 153 Of concern is that patients often fail to share such usage with their medical providers, which can be problematic given the number of drug-herb interactions that can occur. 152 While the evidence is limited regarding whether benefits can be obtained with the use of botanical supplements, some data are available.
Astragalus
Astragalus is an herb derived from the astragalus root, which is commonly used in Chinese medicine, primarily to boost the immune system. In vitro studies reflect the immune properties of astragalus, including enhancement of the antitumor activity of interleukin 2 and potentiation of the activity of macrophages and natural killer cells. 153 While there is not a wealth of evidence, several investigators have evaluated the use of astragalus or astragalus-containing herbal supplements regarding benefits for patients with cancer. [153] [154] [155] [156] For patients with advanced non-small cell lung cancer, a meta-analysis found increased effectiveness of chemotherapy, as evidenced by improved tumor response, decreased risk of death, and improved Karnofsky performance status with use of astragalus supplements. 154 Furthermore, prolonged survival was associated with use of Chinese herbal medicine, which often included astragalus, in patients with acute myeloid leukemia receiving standard treatment. 156 Last, in patients with colorectal cancer receiving oxaliplatin, astragalus was associated with reduced neutropenia. 157 Other benefits in this study included a reduction in cancer-related fatigue and chemotherapy-induced nausea and vomiting.
Although study results show promising outcomes, these studies are small and, in general, poorly designed. Additionally, although astragalus supplementation appears quite safe when used appropriately, larger well-designed trials are needed before findings can be applied to clinical practice. 152 
Melatonin
Melatonin is a pleiotropic hormone secreted primarily by the pineal gland but also by the gastrointestinal tract, perhaps in response to the presence of food. 158 While the exact mechanism of action is unknown, it is thought to regulate the circadian rhythm and help facilitate sleep. Melatonin is available as an over-the-counter supplement and often used to treat a variety of disorders, but it is most commonly used to help relieve jet lag, insomnia, frequency of migraine headaches, and pain and anxiety related to surgery. 158 With aging, melatonin levels decrease, and some research suggests that low levels of melatonin may increase cancer risks. 158 Melatonin is often used by cancer survivors to improve tolerance to treatment, survival time, and quality of life. In pharmacologic doses, melatonin may provide anticarcinogenic benefits through antioxidant, antimitotic, antiproliferative, anti-inflammatory, and immunomodulatory properties; the enhanced cytotoxic action of some chemotherapeutic agents has also been demonstrated. [159] [160] [161] Investigators have reported that individuals working the night shift for many years (20-30 years) had a greater risk for breast and colon cancer, potentially due to lower levels of melatonin. 160 In a systematic review and meta-analysis by Seely et al, reduced mortality was found with the use of melatonin alone by cancer patients with solid tumors or when used in combination with chemotherapy (RR, 0.63; 95% CI, 0.53-0.74; P < .001; RR, 0.60; 95 CI, 0.54-0.67, respectively). 162 Moreover, supplementation with melatonin significantly decreased treatment-related side effects, including asthenia (RR, 0. , in addition to radiotherapy for treatment of glioblastomas, appear to improve survival in a small study, when compared with radiation alone. 163 Conversely, in another study, melatonin supplementation (20 mg/d) did not improve appetite, weight, or quality of life in patients with cachexia and advanced cancer. 164 Supplementation with doses ranging from 20 to 40 mg/d appeared to be well tolerated, with only headache, dizziness, sleepiness, and drowsiness reported as common side effects. 165 Caution is recommended, however, when using melatonin, as moderate potential drug-nutrient interactions exist between melatonin and anticoagulants, antiplatelet, antidiabetic, antihypertensive, anticonvulsants, and immunosuppressive medications. 165 Although melatonin can be obtained from dietary sources, such as wheat grass and rye grass, the question is whether these sources can raise serum levels sufficiently. Therefore, melatonin supplementation appears necessary to obtain the reported benefits associated with its use.
Despite promising findings, a few significant limitations should be noted regarding the use of melatonin. Many of the studies have been conducted by the same investigators. 159, 163 Moreover, most studies were small, and none were blinded. Thus, before melatonin supplementation is widely recommended for cancer survivors, large prospective, doubleblinded, placebo-controlled trials are needed to valid reported findings.
Milk Thistle
Milk thistle is commonly used as a botanical remedy for hepatitis, cirrhosis, liver disease, cancer prevention, and mushroom poisoning. 166 The active ingredient, silymarin, is associated with suppression of hepatic inflammation by providing antioxidant and anti-inflammatory benefits. 166 Minimal safety issues have been reported with the use of milk thistle; therefore, it is generally considered to be safe. 166 Theoretically, milk thistle may have an adverse impact on cytotoxic drugs that act to generate free radicals; however, there are no trials to support or negate these concerns. 166 While milk thistle may be considered safe, the evidence supporting the claims related to its benefits are supported by only a few very small trials. In 1 trial of 50 pediatric patients undergoing treatment for acute lymphoblastic leukemia with chemotherapy-induced hepatotoxicity, participants receiving silymarin had a significant lowering of liver enzymes when compared with a placebo. 167 In a randomized controlled trial, the administration of oral silymarin (420 mg/d) significantly reduced the severity of radiotherapy-induced mucositis and delayed its occurrence. 168 In another study, women undergoing radiation therapy for breast cancer who used a silymarin-based cream (Leviaderm) showed lower incidence and intensity of acute skin reactions. 169 Last, a randomized controlled trial with 37 men following radical prostatectomy demonstrated an improved quality-of-life score, decreased low-density lipoproteins and total cholesterol, and increased serum selenium levels after a 6-month daily combination administration of silymarin and selenium. 170 In conclusion, very little data exist related to the use of milk supplements; therefore, whether supplementation may provide any benefits for cancer survivors is unknown, although supplementation appears safe.
Turmeric
Turmeric is a bright yellow spice derived from the rhizomes of the Curcuma longa plant, a member of the ginger family (Zingiberaceae), which requires a warmer climate to grow. The medicinal effects of turmeric are derived from the yellow pigments found in turmeric, collectively known as curcumin; 3 major curcuminoids have been identified as the active components in turmeric: diferuloylmethane (82%), demethoxycurcumin (15%), and bisdemethoxycurcumin (3%). 171 Curcumin is commonly employed in Chinese and Ayurveda medicine for its antioxidant and anti-inflammatory benefits and is often prescribed for the treatment of gastrointestinal and abdominal complaints. 171 The anticarcinogenic biologic activity of curcumin is linked to its function as an antioxidant, anti-inflammatory agent with an ability to modulate cell proliferation, signaling pathways, transcription factors, and tumor angiogenesis. 171, 172 In a phase II study, curcumin supplementation downregulated nuclear factor κB activity in patients with pancreatic activity. 172 The ability to alter gene transcription and induce apoptosis advocates for a potential utility in cancer chemoprevention and chemotherapy. 172 Thus far, most of the clinical evidence available regarding the use of turmeric/curcumin supplements and possible benefits has been derived from phase I and II studies evaluating the feasibility and tolerance to supplementation. Preliminary evidence suggests that turmeric supplementation may stabilize disease in patients with advanced colorectal cancer in doses of 3.6 g/d when taken for 4 months despite low widespread tissue distribution. 173 A recent phase II trial that enrolled 29 men receiving 3 cycles of docetaxel/prednisone and curcumin (6 g/d for 7 consecutive days plus chemotherapy) for castrationresistant prostate cancer found the following: in the 26 participants who completed the study, 17 had lower prostate-specific antigen; 4 had normalization of levels; and 4 had progression of the cancer. No increase in toxicity-related symptoms over expected complaints was noted. 174 Rao et al investigated whether swishing an oral solution with 400 mg of turmeric in 80 mL of water 6 times per day could be effective for radiation mucositis among participants with head/neck cancers. They found that the turmeric-supplemented solution delayed the onset of oral mucositis and reduced reports of it being intolerable by 49%, when compared with participants using a povidone-iodine solution. 175 Recommended doses range from 1 to 3 g/d, with supplements available as powdered capsules and as fluid extracts or tinctures. 176 Oral supplementation of turmeric or curcumin appears safe, although bioavailability is reportedly low, with doses >4 g/d needed to increase serum levels. 176 Turmeric is also rapidly metabolized following absorption; thus, the extent to which turmeric reaches targeted tissues is not clear. 176 Last, curcumin is known to interfere with cytochrome P450 enzyme systems, thereby potentially leading to reduction in chemotherapy. 176, 177 Potential drug-nutrient interactions may also occur with turmeric supplementation, as moderate interactions with antiplatelet drugs leading to decreased platelet aggregation have been reported. 176, 177 Caution with drugs prescribed for diabetes have been recommended, as turmeric may reduce glucose and hemoglobin A1C levels. 178 In summary, while turmeric supplementation has been shown to convey some benefits in small phase I/II studies and although supplementation appears safe, the evidence thus far is insufficient to recommend its use. However, many clinical trials are currently underway to investigate the effectiveness associated with supplementation; as such, future studies will provide better direction for its use.
Resveratrol
Resveratrol is a polyphenolic compound found in a variety of foods, with the highest levels generally found in peanuts, grapes, and red wine. 179 Recently, resveratrol has been widely marketed with much hype that it can be used to cure anything from Alzheimer's disease to cancer, despite the scarcity of evidence supporting such claims. Preclinical studies reflect a potential chemopreventive role for resveratrol, as it promotes apoptosis, regulates cell cycling, and inhibits cyclooxygenase and prostaglandin synthesis while acting as an antioxidant, thereby preventing DNA damage that can lead to tumor formation. 179, 180 Potential moderate drug-nutrient interactions have been reported between resveratrol and anticoagulation and antiplatelet drugs, thereby increasing the risk for bleeding. 181 Additionally, women with estrogen-sensitive cancers, including breast, uterine, and ovarian cancers, should avoid resveratrol supplements until more is known about resveratrol's potential estrogenic properties. 181 While resveratrol is fairly well absorbed, it is rapidly metabolized, thereby limiting its systemic distribution. 181 
Ginger
Ginger is a spice commonly used as a flavor agent in Indian and Middle Eastern foods. Gingerol and shogaol components have been identified as the active ingredient in ginger, which may provide benefits related to its antispasmodic and antiinflammatory benefits. 182 Ginger is often used by cancer patients to prevent the nausea that is commonly associated with treatment. [183] [184] [185] [186] [187] [188] Ginger is thought to provide antinausea benefits by binding to 5-HT 3 receptor sites and acting as a receptor antagonist in the gastrointestinal tract to inhibit the binding of certain neurotransmitters associated with promoting nausea. 182 Because of the anti-inflammatory properties, ginger can reduce damage to tissues by ROS by upregulating certain detoxification enzyme systems. 182 As exhibited in Table 3 , most of the studies reflect that ginger supplementation in doses ranging from 1 to 1.5 g/d may be effective for reducing the incidence of chemotherapyinduced acute nausea. [183] [184] [185] [186] In the largest study to date, Ryan et al found in a randomized placebo-controlled clinical trial that ginger supplementation in doses >1.5 g/d were not effective in reducing acute nausea related to chemotherapy and that doses of 0.5 and 1.0 g/d significantly reduced the incidence of reported acute nausea (P = .013 and .003, respectively). 185 In this study, patients were enrolled if they had experienced 1 prior episode of nausea after receiving chemotherapy with the antiemetic dexamethasone and a 5-HT 3 receptor antagonist (Zofran, Kytril, etc). Patients were excluded from the study if they were receiving concurrent radiation. Supplementation was prescribed as a 6-day course starting 3 days prior to their scheduled chemotherapy infusion. Study participants were instructed to take 250 mg of ginger, 3 times a day. In contrast, Zick et al reported that study participants randomized to aprepitant and ginger (1 or 2 g/d) following their chemotherapy infusion, vs aprepitant and placebo, were more likely to have acute severe nausea than participants taking only aprepitant. 186 There also was no difference between the groups regarding the prevalence of delayed nausea.
Before widespread use of ginger supplements can be recommended for chemotherapy-induced nausea and vomiting, further studies enrolling larger sample sizes are needed to evaluate whether ginger can be useful as an antiemetic during chemotherapy. Future studies should also examine which type of chemotherapeutic regimens may benefit from the use of ginger supplementation, since some chemotherapy agents are more emetogenic than others. Researchers in Italy are currently enrolling patients receiving highly emetogenic regimens for a prospective placebo-controlled randomized trial comparing ginger supplementation with the new antiemetics regarding the efficacy for acute and delayed nausea and vomiting. 188 Caution is recommended when using ginger supplements while taking prescription medications, such as anticoagulant and antiplatelet drugs, as moderate herbal-medication interactions exist; major interactions may occur with nifedipine. 187 Ginger is thought to be safe except during lactation.
Ginseng
Ginseng is a botanical supplement that has been widely marketed to increase energy and stimulate the immune system. There are many species, with American and Asian species from the Panax genus typically used in available supplements. Ginsenosides are the active ingredient identified with the potential benefits gained from ginseng's anti-inflammatory and cortisol-modulating effects. Improvements in immune function through activation of monocytes, natural killer cells, interleukin 2, and B-lymphocytes have been reported. 189 Additionally, human studies conducted with Asian and American ginseng have found a reduction in cancer-related fatigue. 189, 190 As reflected in Table 4 , a pilot study noted a trend for less cancerrelated fatigue with doses of 2000 mg/d for 8 weeks among participants with stage I-IV cancers receiving chemotherapy or radiation or having recently completed treatment, as compared with placebo. 190 In their follow-up study, Barton et al reconfirmed their initial findings of a reduction in fatigue in the ginseng-supplemented group compared with placebo (P = .003). 191 To gain any apparent benefits of using ginseng supplements, 2000 mg daily is the typical dose recommended. 191, 192 Ginseng is likely safe; however, potential drug-herbal interactions exist between ginseng and warfarin, diabetic medications, and immunosuppressants.
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Potential Adverse Effects of Using Dietary Supplements
The Dietary Supplement Health and Education Act was established to define and regulate the sales of dietary supplements in the United States with oversight by the Food and Drug Administration (FDA). 193 While supplement manufacturers are required to ensure that their products are safe for consumers, they are not required to receive FDA approval nor submit evidence on safety before marketing them. 194 In contrast, pharmaceutical companies must provide safety data prior to selling their products. The FDA does monitor for any safety issues once products are available in the marketplace, and it can issue safety warnings or stipulate their removal when safety concerns arise. However, despite FDA warnings and recommendations to avoid some products, these products are often still widely available on the shelf or online.
Aloe vera, arrowroot juice, black cohosh, chaparral, comfrey, germander, green tea extract, kava, and pennyroyal, to name a few, are herbs that can reportedly cause hepatotoxicity and should be avoided. 195, 196 Additionally, essiac, or Flor Essence, has long been marketed to oncology patients for immune support during antineoplastic treatments due to purported benefits, such as antioxidant, anti-inflammatory, and immunostimulatory benefits associated with its use. 197 Essiac is a combination of burdock root, sheep sorrel root, slippery elm bark, and rhubarb root. Despite the lack of evidence to support its use, essiac continues to be popular with oncology patients. Amygdalin (Laetrile) is another common dietary supplement used by cancer patients. Amygdalin is a cyanogenic glycoside found in plants, nuts, and the pits of fruits (particularly apricots). 198 Since the 1960s, amygdalin has been available in a purified form known as laetrile. 198 In a trial completed by the National Cancer Institute in the 1970s, no benefits were found for amygdalin, but several study participants had cyanide toxicity or elevated serum levels close to cyanide poisoning. 199 Moreover, a systematic review did not find any clinical efficacy for using amygdalin to prevent or treat cancer. 200 While the FDA removed amygdalin from the marketplace, it can be readily obtained online. In addition to being marketed as laetrile, it can also be purchased as vitamin 17.
Challenges
Botanical supplements present unique challenges given that many botanicals are derived from the whole plant, parts of the plant, or plant extracts, which may provide concentrated doses. 201 The presence of contaminates in products is also a challenge, since many may contain pesticides, natural toxins, and heavy metals. The active constituents may vary on the basis of growing and harvesting practices, geography, and manufacture processing, resulting in differences in properties and safety among products. 152 Additionally, the lack of standardization required among products may result in significant variations among available products. Safety is a concern given that many products have not been adequately studied for potential herb-drug interactions.
The conflicting results reported by investigators examining whether supplements may provide any advantages for disease risk reduction, including cancers, are likely due to a number of reasons. Many of the studies completed thus far have been affected by limitations in methodology, including small sample sizes, variations in doses used, different species used, and lack of diversity in terms of sex, ethnicity, health status, and age.
Implications for Practice
Dietary supplements are a billion-dollar business, and the use of such supplements by cancer survivors is common, with many patients failing to report their use to their healthcare practitioners. 5 Given that supplements are widely available and thus easily accessible, a multitude of concerns exist, particularly since data are lacking regarding not only effectiveness and quality control but also safety-especially in terms of possible drug/ herb-nutrient interactions. Information regarding the risk and benefits is available from a number of sources, as outlined in Table 5 . With >55,000 dietary supplements available in the marketplace, it is impossible for clinicians to keep up with all the new options that are continually available. 202, 203 However, information is available from a number of third-party organizations, such as ConsumerLab.com, NSF International, and U.S. Pharmacopeial, which test various dietary supplements on a continuous basis to examine products for quality, strength, and presence of contaminants (microbes, heavy metals, pesticides, etc). Data regarding their clinical findings can be obtained online at their websites, although some may require a subscription to access testing results.
Information about supplement use should be elicited with a nonjudgmental approach in a supportive environment. Patient involvement in making treatment-related decisions is essential for promoting satisfaction with medical care, reducing anxiety, and improving quality of life.
Future Directions
Double-blinded PRCTs are the gold standard for practicing evidence-based medicine and, many times, report findings different from those of observational trials. Hence, PRCTs should be the methodology used moving forward to better understand the role of dietary supplements in cancer prevention and treatment. Such trials should be designed to enroll a diverse population of individuals who are at high risk for developing a nutrient deficiency or currently have a deficiency, since many trials thus far have enrolled primarily healthy non-Hispanic women and men or highly educated participants, such as nurses or physicians. Studies need to be designed that control for confounding factors, such as body weight, physical activity habits, overall diet, prior supplement use, medication use, and presence of genetic polymorphisms known to affect outcomes. Studies also need to be long-term, which allows for ongoing evaluation of continued exposure given that many of the trials completed thus far have found either benefits or adverse effects related to supplement use after many years of supplementation.
Conclusion and Summary
In an effort to obtain any possible benefits for risk reduction, many cancer survivors frequently use a variety of dietary supplements. Examining the relationship between various dietary supplements and cancer outcomes is complicated, as outcomes are likely influenced by many factors, including overall lifestyle habits and health status, type of cancer and treatment, type and doses of supplement and formulation used, and consistency in actually ingesting the supplement, as well as many other covariates previously described. Most studies have not demonstrated any benefits for healthy people related to the use of various dietary supplements. Whether supplements such as MVMs/botanicals will convey any benefits to cancer survivors is unclear. Cancer patients should be encouraged to obtain micronutrients and phytonutrients associated with a reduced risk for cancer by consuming a prudent diet rich in fruits, vegetables, legumes, nuts, and seeds, and avoiding processed and fast foods. Living a healthy lifestyle has been associated more with a reduced risk for developing cancer and other chronic diseases than using dietary supplements. National cancer organizations support the use of taking a standard MVM supplement that does not exceed 100% of the recommended daily allowance when dietary nutrient intake is severely inadequate or nutrition deficiencies are exhibited. 6, 25 Given the extent of research reflecting that vitamin D supplementation may be needed to promote serum levels >20 ng/mL for skeletal health, vitamin D levels should be periodically assessed to determine if supplementation is necessary. Practice guidelines recommend that a trained professional who can provide guidance regarding supplement use should be consulted. 25 A variety of online resources are available that provide reliable and accurate information to assist practitioners in providing advice (see Table 5 ).
